 |
|
Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells
Ha Ra Gu, Su Cheol Park, Su Jin Choi, Jae Cheol Lee, You Cheoul Kim, Chul Ju Han, Jin Kim, Ki Young Yang, Yeon Joo Kim, Geum Youb Noh, So Hyeon No, Jae-Hoon Jeong
Clin Mol Hepatol. 2015;21(1):49-59. Published online 2015 Mar 25 DOI: https://doi.org/10.3350/cmh.2015.21.1.49
|
|
Citations to this article as recorded by
 A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment
Pantha Prodip Ray, Mohammad Ashraful Islam, Mohammad Safiqul Islam, Aixia Han, Peiwu Geng, Md. Abdul Aziz, Abdullah Al Mamun
Frontiers in Pharmacology.2024;[Epub] CrossRef Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition
Sunanda Singh, Hector J. Gomez, Shreya Thakkar, Samara P. Singh, Ashutosh S. Parihar
International Journal of Molecular Sciences.2023; 24(5): 4722. CrossRef Natural Compounds as Integrative Therapy for Liver Protection
against Inflammatory and Carcinogenic Mechanisms: From
Induction to Molecular Biology Advancement
Antara Banerjee, Sushmitha Sriramulu, Roberto Catanzaro, Fang He, Yashna Chabria, Baskar Balakrishnan, Sruthi Hari, Antonio Ayala, Mario Muñoz, Surajit Pathak, Francesco Marotta
Current Molecular Medicine.2023; 23(3): 216. CrossRef Design, Synthesis and Biological Evaluation of Glycosylated Derivatives of Silibinin as Potential Anti-Tumor Agents
Jian-Jun Xi, Yu Cao, Ruo-Yu He, Jian-Kang Zhang, Yan-Mei Zhao, Qiao Tong, Jian-Feng Bao, Yi-Chen Dong, Rang-Xiao Zhuang, Jin-Song Huang, Yongping Chen, Shou-Rong Liu
Drug Design, Development and Therapy.2023; Volume 17: 2063. CrossRef Contrary to known silibinin is not an anticancer agent and liver protective supplement
Deniz Şumnulu
Genetika.2023; 55(2): 553. CrossRef Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
Tomas Koltai, Larry Fliegel
Journal of Evidence-Based Integrative Medicine.2022; 27: 2515690X2110688. CrossRef Mechanistic Insights into the Pharmacological Significance of Silymarin
Karan Wadhwa, Rakesh Pahwa, Manish Kumar, Shobhit Kumar, Prabodh Chander Sharma, Govind Singh, Ravinder Verma, Vineet Mittal, Inderbir Singh, Deepak Kaushik, Philippe Jeandet
Molecules.2022; 27(16): 5327. CrossRef Experimental Models of Hepatocellular Carcinoma—A Preclinical Perspective
Alexandru Blidisel, Iasmina Marcovici, Dorina Coricovac, Florin Hut, Cristina Adriana Dehelean, Octavian Marius Cretu
Cancers.2021; 13(15): 3651. CrossRef Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma
Tao Wang, Qiting Zhang, Ning Wang, Ziqi Liu, Bin Zhang, Yufen Zhao
Current Medicinal Chemistry.2021; 28(16): 3107. CrossRef Autophagy: A Potential Therapeutic Target of Polyphenols in Hepatocellular Carcinoma
Chandramohan Kiruthiga, Kasi Pandima Devi, Seyed M. Nabavi, Anupam Bishayee
Cancers.2020; 12(3): 562. CrossRef Is the era of sorafenib over? A review of the literature
Guanghan Fan, Xuyong Wei, Xiao Xu
Therapeutic Advances in Medical Oncology.2020; 12: 175883592092760. CrossRef Chronic Liver Disease and Silymarin: A Biochemical and Clinical Review
Sean P. Tighe, Daud Akhtar, Umair Iqbal, Aijaz Ahmed
Journal of Clinical and Translational Hepatology.2020; 8(4): 1. CrossRef Flavonolignans: One Step Further in the Broad-Spectrum Approach of Cancer
Diana S. Antal, Florina Ardelean, Stefana Avram, Ioana Z. Pavel, Corina Danciu, Codruta Soica, Cristina Dehelean
Anti-Cancer Agents in Medicinal Chemistry.2020; 20(15): 1817. CrossRef Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma
Jeong-Ju Yoo, Su Yu, Juri Na, Kyungmin Kim, Young Cho, Yun Lee, Eun Cho, Jeong-Hoon Lee, Yoon Kim, Hyewon Youn, Jung-Hwan Yoon
International Journal of Molecular Sciences.2019; 20(6): 1292. CrossRef Apoptotic Pathway as the Therapeutic Target for Anticancer Traditional Chinese Medicines
Weixiao An, Honglin Lai, Yangyang Zhang, Minghua Liu, Xiukun Lin, Shousong Cao
Frontiers in Pharmacology.2019;[Epub] CrossRef The Story of Nanoparticles in Differentiation of Stem Cells into Neural Cells
Vajihe Asgari, Amir Landarani-Isfahani, Hossein Salehi, Noushin Amirpour, Batool Hashemibeni, Saghar Rezaei, Hamid Bahramian
Neurochemical Research.2019; 44(12): 2695. CrossRef Poly(glycerol methacrylate)-based degradable nanoparticles for delivery of small interfering RNA
Noha G. Morsi, Shimaa M. Ali, Sherouk S. Elsonbaty, Ahmed A. Afifi, Mostafa A. Hamad, Hui Gao, Mahmoud Elsabahy
Pharmaceutical Development and Technology.2018; 23(4): 387. CrossRef Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT
Jie Mao, Hongbao Yang, Tingting Cui, Pan Pan, Nadia Kabir, Duo Chen, Jinyan Ma, Xingyi Chen, Yijun Chen, Yong Yang
European Journal of Pharmacology.2018; 832: 39. CrossRef Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases
Ludovico Abenavoli, Angelo A. Izzo, Natasa Milić, Carla Cicala, Antonello Santini, Raffaele Capasso
Phytotherapy Research.2018; 32(11): 2202. CrossRef A circRNA–miRNA–mRNA network identification for exploring underlying pathogenesis and therapy strategy of hepatocellular carcinoma
Dan-dan Xiong, Yi-wu Dang, Peng Lin, Dong-yue Wen, Rong-quan He, Dian-zhong Luo, Zhen-bo Feng, Gang Chen
Journal of Translational Medicine.2018;[Epub] CrossRef Silibinin induces hepatic stellate cell cycle arrest via enhancing p53/p27 and inhibiting Akt downstream signaling protein expression
Devaraj Ezhilarasan, Jonathan Evraerts, Brice Sid, Pedro Buc Calderon, Sivanesan Karthikeyan, Etienne Sokal, Mustapha Najimi
Hepatobiliary & Pancreatic Diseases International.2017; 16(1): 80. CrossRef Targeting STAT3 with silibinin to improve cancer therapeutics
Joaquim Bosch-Barrera, Bernardo Queralt, Javier A. Menendez
Cancer Treatment Reviews.2017; 58: 61. CrossRef FGF8 promotes cell proliferation and resistance to EGFR inhibitors via upregulation of EGFR in human hepatocellular carcinoma cells
Yuanmin Pei, Xueling Sun, Xiwei Guo, Huashan Yin, Le Wang, Fugu Tian, Hongxi Jing, Xiaobo Liang, Jun Xu, Pengcheng Shi
Oncology Reports.2017; 38(4): 2205. CrossRef Silibinin suppresses bladder cancer cell malignancy and chemoresistance in an NF-κB signal-dependent and signal-independent manner
Yi Sun, Zhenfeng Guan, Wencai Zhao, Yazhuo Jiang, Qing Li, Yongyi Cheng, Yonggang Xu
International Journal of Oncology.2017; 51(4): 1219. CrossRef Melatonin enhances sorafenib actions in human hepatocarcinoma cells by inhibiting mTORC1/p70S6K/HIF-1α and hypoxia-mediated mitophagy
Néstor Prieto-Domínguez, Carolina Méndez-Blanco, Sara Carbajo-Pescador, Flavia Fondevila, Andrés García-Palomo, Javier González-Gallego, José L. Mauriz
Oncotarget.2017; 8(53): 91402. CrossRef Silibinin: a potential old drug for cancer therapy
Xing-Xing Zhu, Ya-Hui Ding, Yi Wu, Lin-Yan Qian, Hai Zou, Qiang He
Expert Review of Clinical Pharmacology.2016; 9(10): 1323. CrossRef Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14
Yuri Cho, Yun Bin Lee, Jeong-Hoon Lee, Dong Hyeon Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jong In Kim, Jong Hun Im, Jung Hwan Lee, Eun Ju Oh, Jung-Hwan Yoon, Seung Up Kim
PLOS ONE.2016; 11(8): e0160822. CrossRef Novel Investigations of Flavonoids as Chemopreventive Agents for Hepatocellular Carcinoma
Chen-Yi Liao, Ching-Chang Lee, Chi-chang Tsai, Chao-Wen Hsueh, Chih-Chiang Wang, I-Hung Chen, Ming-Kai Tsai, Mei-Yu Liu, An-Tie Hsieh, Kuan-Jen Su, Hau-Ming Wu, Shih-Chung Huang, Yi-Chen Wang, Chien-Yao Wang, Shu-Fang Huang, Yen-Cheng Yeh, Ren-Jy Ben, Sha
BioMed Research International.2015; 2015: 1. CrossRef
|